Interactions
In humans, the absorption of milk is inhibited when tetracycline hydrochloride, sodium EDTA, and milk are taken simultaneously; however, this inhibition is counteracted by the concurrent intake of EDTA.
Administering cortisol 1-6 hours before EDTA injection reduces the degree of vascular damage in adrenalectomized rats; however, administration of cortisol delayed until 15 minutes before EDTA injection has no protective effect.
Non-human toxicity values Mouse intraperitoneal LD50: 330 mg/kg
Rat intraperitoneal LD50: >2.0 g/kg
Rat intraperitoneal LD50: 4000 mg/kg body weight

[1]. Artifact-inducing enrichment of ethylenediaminetetraacetic acid and ethyleneglycoltetraacetic acid on anion exchange resins. Anal Biochem. 2011 May 1;412(1):34-9.

[2]. The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes. Clin Chem Lab Med. 2007;45(5):565-76.

[3]. Chelation therapy in the treatment of cardiovascular diseases. J Clin Lipidol. 2016 Jan-Feb;10(1):58-62.

[4]. The effect of ethylenediaminetetra-acetic acid on the cell walls of some gram-negative bacteria. J Gen Microbiol. 1965 Jun;39(3):385-99.

[5]. Ethylenediaminetetraacetic acid induces antioxidant and anti-inflammatory activities in experimental liver fibrosis. Redox Rep. 2011;16(2):62-70.

[6]. Remediation of heavy metals contaminated silty clay loam soil by column extraction with ethylenediaminetetraacetic acid and nitrilo triacetic acid. Journal of Environmental Engineering, 2017, 143(8): 04017026.

[7]. Ethylenediaminetetraacetic acid (EDTA) enhances cAMP production in human TDAG8-expressing cells. Biochem Biophys Res Commun. 2022 Oct 20;626:15-20.

Tetrasodium ethylenediaminetetraacetate (EDTA) is a chelating agent that chelates various polyvalent cations, such as calcium. It is used in pharmaceutical manufacturing and as a food additive.
Therapeutic Uses
When used as a powder chelating agent, tetrasodium EDTA should not come into direct contact with the eyes unless neutralized first, as the resulting solution is alkaline enough to damage the eyes.
Researchers tested the efficacy of tetrasodium EDTA in removing biofilms formed from salivary inoculum or pure cultures of Candida albicans on polymethyl methacrylate (PMMA) denture base discs or toothbrushes used normally for 4–8 weeks. Its virus neutralization efficiency was also determined. After overnight (16 hours) treatment with a 4% (w/v) tetrasodium EDTA solution, the number of viable bacteria in salivary and Candida albicans biofilms decreased by ≥99%. Biofilm removal was confirmed using confocal laser scanning microscopy. The presence or absence of sucrose during biofilm formation had no effect on the bactericidal effect. Prolonged treatment of polymethyl methacrylate (PMMA) with tetrasodium EDTA does not affect the subsequent formation of Candida albicans biofilms or the surface roughness of PMMA, but it does reduce the subsequent formation of biofilms from salivary inoculum. The infectivity of herpes simplex virus and poliovirus suspensions was reduced by more than 99.99% after 1 hour and 2 hours of treatment, respectively. Tetrasodium EDTA solution effectively disinfects toothbrushes and PMMA discs, causing biofilm detachment and rapidly neutralizing both non-enveloped and enveloped viruses. Dentures and toothbrushes are susceptible to contamination by bacterial biofilms and viruses. Therefore, rapid, effective, economical, non-toxic, and easy-to-implement disinfection methods are needed. These studies demonstrate the disinfection value of tetrasodium EDTA solution in oral care. Central venous catheter (CVC)-associated bloodstream infections (BSIs) are known to increase morbidity and mortality in hospitalized and outpatient patients, including those with hematologic malignancies and those undergoing hemodialysis or home infusion therapy. Biofilm-associated microorganisms on the lumen of these catheters have reduced susceptibility to antimicrobial agents. This study tested the bactericidal effect of tetrasodium EDTA as a catheter locking solution on several clinically relevant microbial biofilms. In a model system, biofilms of Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Candida albicans were cultured to approximately 1 × 10⁵ CFU/cm², followed by locking with tetrasodium EDTA. Changes in biofilms before and after locking with 40 mg/mL tetrasodium EDTA for 21 hours were compared. The results showed that the viable bacterial counts of all tested microorganisms were significantly reduced after locking (P < 0.05). Antimicrobial locking with 40 mg/mL⁻¹ tetrasodium EDTA for at least 21 hours can significantly reduce and potentially eradicate central venous catheter (CVC)-associated clinically relevant microbial biofilms.
Experimental Applications: Intravenous injection of 50 mg/kg Trilon B into rabbits with lithium chloride poisoning and intraperitoneal injection of 150-175 mg/kg Trilon B into mice both showed significant therapeutic effects.
...Tetrasodium EDTA can effectively treat corneal lime burns and can also be used as a chelating agent to treat hypercalcemia by removing calcium from the blood.

380.018

64-02-8

Ethylenediaminetetraacetic acid;60-00-4

6144

White to off-white solid powder

6.9 g/cm3

614.2ºC at 760 mmHg

>300 °C(lit.)

325.2ºC

0

10

7

24

293

0

C(=O)(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC([O-])=O)[O-].[Na+4]

UEUXEKPTXMALOB-UHFFFAOYSA-J

InChI=1S/C10H16N2O8.4Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;;/q;4*+1/p-4

tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate

Tetrine Edetate Sodium Trilon B

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)